183 related articles for article (PubMed ID: 19237284)
1. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
[TBL] [Abstract][Full Text] [Related]
2. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
4. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
Mukherjee P; Desai P; Zhou YD; Avery M
J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
[TBL] [Abstract][Full Text] [Related]
5. A new assay for the discovery of Bcl-XL inhibitors.
Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
7. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms.
Qian J; Voorbach MJ; Huth JR; Coen ML; Zhang H; Ng SC; Comess KM; Petros AM; Rosenberg SH; Warrior U; Burns DJ
Anal Biochem; 2004 May; 328(2):131-8. PubMed ID: 15113688
[TBL] [Abstract][Full Text] [Related]
9. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
[TBL] [Abstract][Full Text] [Related]
10. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
Denisov AY; Sprules T; Fraser J; Kozlov G; Gehring K
Biochemistry; 2007 Jan; 46(3):734-40. PubMed ID: 17223694
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of Bax and Bad.
Solomon VR; Almnayan D; Lee H
Eur J Med Chem; 2017 Sep; 137():156-166. PubMed ID: 28586716
[TBL] [Abstract][Full Text] [Related]
12. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
Xu H; Tai J; Ye H; Kang CB; Yoon HS
Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
Vo DD; Gautier F; Juin P; Grée R
Eur J Med Chem; 2012 May; 51():286-93. PubMed ID: 22425031
[TBL] [Abstract][Full Text] [Related]
15. Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.
Melkko S; Mannocci L; Dumelin CE; Villa A; Sommavilla R; Zhang Y; Grütter MG; Keller N; Jermutus L; Jackson RH; Scheuermann J; Neri D
ChemMedChem; 2010 Apr; 5(4):584-90. PubMed ID: 20229565
[TBL] [Abstract][Full Text] [Related]
16. Oral disinfectants inhibit protein-protein interactions mediated by the anti-apoptotic protein Bcl-xL and induce apoptosis in human oral tumor cells.
Gräber M; Hell M; Gröst C; Friberg A; Sperl B; Sattler M; Berg T
Angew Chem Int Ed Engl; 2013 Apr; 52(16):4487-91. PubMed ID: 23512547
[No Abstract] [Full Text] [Related]
17. Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Perez HL; Banfi P; Bertrand J; Cai ZW; Grebinski JW; Kim K; Lippy J; Modugno M; Naglich J; Schmidt RJ; Tebben A; Vianello P; Wei DD; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3946-50. PubMed ID: 22608961
[TBL] [Abstract][Full Text] [Related]
18. Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.
Dömling A; Antuch W; Beck B; Schauer-Vukasinović V
Bioorg Med Chem Lett; 2008 Jul; 18(14):4115-7. PubMed ID: 18583128
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD
ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol.
Priyadarshi A; Roy A; Kim KS; Kim EE; Hwang KY
Biochem Biophys Res Commun; 2010 Apr; 394(3):515-21. PubMed ID: 20206602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
